The nonsurgical management of early stage (T1/2 N0 M0) laryngeal cancer: A population analysis

被引:2
|
作者
Lee, Kevin C. [1 ]
Chuang, Sung-Kiang [2 ,3 ]
机构
[1] New York Presbyterian Columbia Univ, Irving Med Ctr, Div Oral & Maxillofacial Surg, New York, NY USA
[2] Univ Penn, Dept Oral & Maxillofacial Surg, Philadelphia, PA 19104 USA
[3] Brockton Oral & Maxillofacial Surg Inc, Dept Oral & Maxillofacial Surg, Good Samaritan Med Ctr, Brockton, MA USA
关键词
SQUAMOUS-CELL CARCINOMA; EARLY GLOTTIC CANCER; RADIATION-THERAPY; CONCURRENT CHEMORADIOTHERAPY; PROGNOSTIC-FACTORS; LOCAL-CONTROL; RADIOTHERAPY; PRESERVATION; CHEMOTHERAPY; SURGERY;
D O I
10.1016/j.oooo.2020.01.006
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background. The purpose of this study was to evaluate the patterns of care and survival in the nonsurgical management of early-stage (T1/2 N0 M0) laryngeal cancer. Study Design. This was a retrospective cohort study using data from the Surveillance, Epidemiology, and End Results (SEER) database during the period 2004 to 2015. Patients diagnosed with T1/2 N0 M0 laryngeal SCC definitively treated without surgery were included. Study predictors were age, gender, race, marital status, histologic grade, stage, and management strategy defined as radiotherapy (RT), chemotherapy, chemoradiotherapy (CRT), or no treatment. Study outcomes were overall survival (OS) and disease-specific survival (DSS). Results. In total, 3221 patients comprised the final sample. Over half of the lesions were stage I (63.8%); 74.0%, 24.8%, and 1.2% were located in the glottis, supraglottis, and subglottis, respectively. RT (77.6%) was the preferred nonsurgical treatment modality, followed by CRT (12.7%). A greater proportion of patients with stage II disease (25.1%) received CRT compared with those with stage I (5.6%). Similarly, patients receiving CRT were significantly younger and more likely to present with higher-grade lesions located in the supraglottis and subglottis. In the multivariate model, the risks of both disease-specific and overall death were increased by age, male gender, supraglottic and subglottic location, stage II disease, CRT, and no treatment. Conclusions. Definitive RT was the preferred treatment modality regardless of tumor characteristics. CRT was more often selectively reserved for younger patients with higher grade, stage II tumors located in the supraglottis and subglottis. This approach may be driven by the poorer rates of survival associated with these particular characteristics. CRT did not appear to improve survival in comparison with RT after controlling for subsite and disease severity; however, future clinical studies are required to validate this finding.
引用
收藏
页码:18 / 24
页数:7
相关论文
共 50 条
  • [21] ARE THE CURRENT MANAGEMENT STRATEGIES FOR T1/T2 N0 OESOPHAGEAL CANCER OPTIMAL?
    Evans, J.
    Pande, R.
    Beardsmore, D.
    Corless, D.
    Crisp, W.
    Cheruvu, C.
    GUT, 2012, 61 : A262 - A262
  • [22] Endocavitary contact radiation therapy for ultrasonographically staged T1 N0 and T2 N0 rectal cancer
    Christoforidis, D.
    McNally, M. P.
    Jarosek, S. L.
    Madoff, R. D.
    Finne, C. O.
    BRITISH JOURNAL OF SURGERY, 2009, 96 (04) : 430 - 436
  • [23] ARE THE CURRENT MANAGEMENT STRATEGIES FOR T1/T2 N0 OESOPHAGEAL CANCER OPTIMAL?
    Evans, R.
    Evans, J. P.
    Kirby, G.
    Curran, F.
    Cheruvu, C. V. N.
    GUT, 2015, 64 : A475 - A475
  • [24] Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC)
    Zimmermann, Frank B.
    Geinitz, Hans
    Schill, Sabine
    Thamm, Reinhard
    Nieder, Carsten
    Schratzenstaller, Ulrich
    Molls, Michael
    ACTA ONCOLOGICA, 2006, 45 (07) : 796 - 801
  • [25] Microvascular density in T1-T4, N0, M0 colorectal carcinomas and prognosis
    Uribarrena, A. R.
    Ortego, J.
    Fuentes, J.
    Raventos, N.
    Parra, P.
    Uribarrena, E. R.
    HISTOPATHOLOGY, 2008, 53 : 168 - 168
  • [26] Factors Affecting Outcomes of Limited-Stage I, IIA (T1-T2, N0, M0) Small Cell Lung Cancer: An Analysis of the National Cancer Database
    Abdullah, H. M.
    Das, A. C.
    Abughanimeh, O. K.
    Muir, K. -L.
    Sharma, B. B.
    Marr, A. S.
    Smith, L. M.
    Ganti, A. K.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S677 - S677
  • [27] The prognosis of T1a, T1b N0 M0, HER2+patients in Korea
    Lee, J. W.
    Moon, H-G
    Han, W.
    Noh, D-Y
    CANCER RESEARCH, 2012, 72
  • [28] Immunohistochemically detected micrometastases in peribronchial and mediastinal lymph nodes from patients with T1, N0, M0 pulmonary adenocarcinomas
    Goldstein, NS
    Mani, A
    Chmielewski, G
    Welsh, R
    Pursel, S
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2000, 24 (02) : 274 - 279
  • [29] Comparison of external beam treatment techniques for T1-2, N0, M0 glottic cancers
    Camingue, Pamela
    Christian, Rochelle
    Ng, Davin
    Williams, Preston
    Amin, Mayankkumar
    Roniger, Dominique L.
    MEDICAL DOSIMETRY, 2012, 37 (02) : 221 - 224
  • [30] Rectal cancer at the crossroads: The dilemma of clinically staged T3, N0,M0 disease
    Kachnic, Lisa A.
    Hong, Theodore S.
    Ryan, David P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) : 350 - 351